Why the study?
Does sulfinpyrazone improve platelet function in patients after coronary artery bypass grafting?
Does sulfinpyrazone improve platelet function in patients after coronary artery bypass grafting?
Sulfinpyrazone significantly improves platelet survival and reduces platelet activation markers in patients 6 months after coronary artery bypass grafting.
Authors
No takes yet. Share an insight, caveat, or question.
Supports sulfinpyrazone consideration for post-CABG platelet modulation; confirms RCT superiority over placebo on key markers.
Cade et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: